UA75052C2 - Oxabispidine compounds being useful in treatment of cardiac arrhythmias - Google Patents

Oxabispidine compounds being useful in treatment of cardiac arrhythmias Download PDF

Info

Publication number: UA75052C2
Authority: UA; Ukraine
Prior art keywords: oxa; benzonitrile; formula; compound; diazadicyclo
Prior art date: 1999-10-18

Application number

UA2002043168A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-18

Filing date

2000-10-13

Publication date

2006-03-15

2000-10-13 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-03-15 Publication of UA75052C2 publication Critical patent/UA75052C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 528
206010003119 arrhythmia Diseases 0.000 title claims abstract description 26
238000011282 treatment Methods 0.000 title claims abstract description 19
230000006793 arrhythmia Effects 0.000 claims abstract description 17
230000001746 atrial effect Effects 0.000 claims abstract description 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 681
238000006243 chemical reaction Methods 0.000 claims description 114
125000000217 alkyl group Chemical group 0.000 claims description 88
229910052736 halogen Inorganic materials 0.000 claims description 85
150000002367 halogens Chemical class 0.000 claims description 85
125000001424 substituent group Chemical group 0.000 claims description 77
238000000034 method Methods 0.000 claims description 76
229910052799 carbon Inorganic materials 0.000 claims description 75
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 72
125000003118 aryl group Chemical group 0.000 claims description 71
229910052740 iodine Inorganic materials 0.000 claims description 68
229910052739 hydrogen Inorganic materials 0.000 claims description 66
125000004093 cyano group Chemical group *C#N 0.000 claims description 62
239000002904 solvent Substances 0.000 claims description 61
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 56
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
238000004519 manufacturing process Methods 0.000 claims description 37
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 34
-1 4-(4-pyridinyl)butyl Chemical group 0.000 claims description 33
239000002585 base Substances 0.000 claims description 31
125000002947 alkylene group Chemical group 0.000 claims description 29
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 27
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
125000004432 carbon atom Chemical group C* 0.000 claims description 21
125000005843 halogen group Chemical group 0.000 claims description 21
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 21
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 claims description 18
229910052757 nitrogen Inorganic materials 0.000 claims description 17
239000003054 catalyst Substances 0.000 claims description 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
125000000623 heterocyclic group Chemical group 0.000 claims description 12
229910052760 oxygen Inorganic materials 0.000 claims description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
125000005842 heteroatom Chemical group 0.000 claims description 11
239000001301 oxygen Substances 0.000 claims description 11
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
230000003647 oxidation Effects 0.000 claims description 10
238000007254 oxidation reaction Methods 0.000 claims description 10
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 10
230000009467 reduction Effects 0.000 claims description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical group C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
125000004104 aryloxy group Chemical group 0.000 claims description 9
125000004429 atom Chemical group 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
239000011630 iodine Substances 0.000 claims description 9
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
125000004430 oxygen atom Chemical group O* 0.000 claims description 8
238000010511 deprotection reaction Methods 0.000 claims description 7
230000002140 halogenating effect Effects 0.000 claims description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
125000004043 oxo group Chemical group O=* 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
238000007363 ring formation reaction Methods 0.000 claims description 6
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
230000002861 ventricular Effects 0.000 claims description 6
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 5
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 5
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
239000011593 sulfur Chemical group 0.000 claims description 5
230000009466 transformation Effects 0.000 claims description 5
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
239000012453 solvate Chemical class 0.000 claims description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
125000006308 propyl amino group Chemical group 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
239000003377 acid catalyst Substances 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
239000004202 carbamide Substances 0.000 claims description 2
229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
150000002829 nitrogen Chemical class 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
101150046432 Tril gene Proteins 0.000 claims 3
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
241000982822 Ficus obtusifolia Species 0.000 claims 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical group O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
235000006408 oxalic acid Nutrition 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
150000003254 radicals Chemical class 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract description 2
206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 248
239000000203 mixture Substances 0.000 description 138
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 108
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 90
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 78
239000000243 solution Substances 0.000 description 78
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
239000000047 product Substances 0.000 description 40
238000010992 reflux Methods 0.000 description 40
239000011541 reaction mixture Substances 0.000 description 39
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
238000002360 preparation method Methods 0.000 description 35
239000010410 layer Substances 0.000 description 34
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
238000005481 NMR spectroscopy Methods 0.000 description 26
230000015572 biosynthetic process Effects 0.000 description 26
239000003960 organic solvent Substances 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
239000000543 intermediate Substances 0.000 description 21
239000012044 organic layer Substances 0.000 description 21
VZSXFJPZOCRDPW-UHFFFAOYSA-N carbanide;trioxorhenium Chemical compound [CH3-].O=[Re](=O)=O VZSXFJPZOCRDPW-UHFFFAOYSA-N 0.000 description 20
239000000706 filtrate Substances 0.000 description 19
150000001721 carbon Chemical group 0.000 description 18
BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 18
229910000027 potassium carbonate Inorganic materials 0.000 description 18
239000012071 phase Substances 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 17
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
235000011181 potassium carbonates Nutrition 0.000 description 16
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 15
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
239000012043 crude product Substances 0.000 description 14
238000001914 filtration Methods 0.000 description 14
239000003921 oil Substances 0.000 description 14
238000000746 purification Methods 0.000 description 14
239000002253 acid Substances 0.000 description 13
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
238000004587 chromatography analysis Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
229920006395 saturated elastomer Polymers 0.000 description 12
239000000377 silicon dioxide Substances 0.000 description 12
239000007787 solid Substances 0.000 description 12
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
125000005233 alkylalcohol group Chemical group 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
125000004122 cyclic group Chemical group 0.000 description 11
230000000694 effects Effects 0.000 description 11
229910052938 sodium sulfate Inorganic materials 0.000 description 11
235000011152 sodium sulphate Nutrition 0.000 description 11
239000000126 substance Substances 0.000 description 11
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 10
238000009835 boiling Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 10
238000003756 stirring Methods 0.000 description 10
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000008901 benefit Effects 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
229910052731 fluorine Inorganic materials 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
125000006239 protecting group Chemical group 0.000 description 9
DMKUNHJZZHMFFE-UHFFFAOYSA-N 3-(4-cyanoanilino)propyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCNC1=CC=C(C#N)C=C1 DMKUNHJZZHMFFE-UHFFFAOYSA-N 0.000 description 8
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
238000004821 distillation Methods 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
238000001816 cooling Methods 0.000 description 7
239000011737 fluorine Substances 0.000 description 7
239000012458 free base Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
229940077388 benzenesulfonate Drugs 0.000 description 6
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 6
239000013078 crystal Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 6
229940011051 isopropyl acetate Drugs 0.000 description 6
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 6
229940098779 methanesulfonic acid Drugs 0.000 description 6
238000002414 normal-phase solid-phase extraction Methods 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
235000012239 silicon dioxide Nutrition 0.000 description 6
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000003416 antiarrhythmic agent Substances 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000005984 hydrogenation reaction Methods 0.000 description 5
229910052763 palladium Inorganic materials 0.000 description 5
125000003170 phenylsulfonyl group Chemical class C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 5
125000004076 pyridyl group Chemical group 0.000 description 5
ULSAJQMHTGKPIY-UHFFFAOYSA-N 1-chloro-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CCl ULSAJQMHTGKPIY-UHFFFAOYSA-N 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 4
MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
239000012359 Methanesulfonyl chloride Substances 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
125000002015 acyclic group Chemical group 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
239000000908 ammonium hydroxide Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
239000003862 glucocorticoid Substances 0.000 description 4
238000005342 ion exchange Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
150000004682 monohydrates Chemical class 0.000 description 4
239000007800 oxidant agent Substances 0.000 description 4
239000003444 phase transfer catalyst Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
125000000719 pyrrolidinyl group Chemical group 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
NHDLUSFFYRBOLY-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-benzyl-1,5-diazocane-3,7-diol Chemical compound C1C(O)CN(S(=O)(=O)C=2C=CC=CC=2)CC(O)CN1CC1=CC=CC=C1 NHDLUSFFYRBOLY-UHFFFAOYSA-N 0.000 description 3
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 3
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
102000004257 Potassium Channel Human genes 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000001345 alkine derivatives Chemical group 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
229940092714 benzenesulfonic acid Drugs 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
108020001213 potassium channel Proteins 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000376 reactant Substances 0.000 description 3
230000002336 repolarization Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000033764 rhythmic process Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
238000005406 washing Methods 0.000 description 3
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
QQZUTVCAQZLTTH-UHFFFAOYSA-N 2-(4-cyanophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=C(C#N)C=C1 QQZUTVCAQZLTTH-UHFFFAOYSA-N 0.000 description 2
SMFFZOQLHYIRDA-UHFFFAOYSA-N 3,4-dimethoxyphenol Chemical compound COC1=CC=C(O)C=C1OC SMFFZOQLHYIRDA-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
OMVNWHFRVCCONY-UHFFFAOYSA-N 4-(4-chlorobutyl)pyridine Chemical compound ClCCCCC1=CC=NC=C1 OMVNWHFRVCCONY-UHFFFAOYSA-N 0.000 description 2
DIGCPYJRPMHBNF-UHFFFAOYSA-N 4-(4-cyanophenyl)butyl methanesulfonate Chemical compound CS(=O)(=O)OCCCCC1=CC=C(C#N)C=C1 DIGCPYJRPMHBNF-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000700198 Cavia Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
KXPZAIZTRSPNBA-UHFFFAOYSA-N [4-(benzenesulfonyl)-6-(hydroxymethyl)morpholin-2-yl]methanol Chemical compound C1C(CO)OC(CO)CN1S(=O)(=O)C1=CC=CC=C1 KXPZAIZTRSPNBA-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
229910000085 borane Inorganic materials 0.000 description 2
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000007787 electrohydrodynamic spraying Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000010907 mechanical stirring Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
150000002978 peroxides Chemical class 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
230000033458 reproduction Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000005070 sampling Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
WPXMQHNCZJXSCW-UHFFFAOYSA-N tert-butyl n-[3-(4-cyanophenoxy)-2-hydroxypropyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC(O)COC1=CC=C(C#N)C=C1 WPXMQHNCZJXSCW-UHFFFAOYSA-N 0.000 description 2
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 description 1
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
KYLUAQBYONVMCP-UHFFFAOYSA-N (2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P KYLUAQBYONVMCP-UHFFFAOYSA-N 0.000 description 1
PNKZBZPLRKCVLI-UHFFFAOYSA-N (2-methylpropan-2-yl)oxybenzene Chemical compound CC(C)(C)OC1=CC=CC=C1 PNKZBZPLRKCVLI-UHFFFAOYSA-N 0.000 description 1
LAGMBWGVPMDMBP-GHMZBOCLSA-N (2s,6s)-4-(benzenesulfonyl)-2,6-bis(iodomethyl)morpholine Chemical compound C1[C@@H](CI)O[C@H](CI)CN1S(=O)(=O)C1=CC=CC=C1 LAGMBWGVPMDMBP-GHMZBOCLSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000006530 (C4-C6) alkyl group Chemical group 0.000 description 1
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
ATWLRNODAYAMQS-UHFFFAOYSA-N 1,1-dibromopropane Chemical compound CCC(Br)Br ATWLRNODAYAMQS-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
HUXJXNSHCKHFIL-UHFFFAOYSA-N 1-(2-bromoethoxy)-2-methoxyethane Chemical compound COCCOCCBr HUXJXNSHCKHFIL-UHFFFAOYSA-N 0.000 description 1
IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
ROKZAMCDHKVZIQ-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutane Chemical compound CC(C)(C)CCBr ROKZAMCDHKVZIQ-UHFFFAOYSA-N 0.000 description 1
MNZAKDODWSQONA-UHFFFAOYSA-N 1-dibutylphosphorylbutane Chemical compound CCCCP(=O)(CCCC)CCCC MNZAKDODWSQONA-UHFFFAOYSA-N 0.000 description 1
PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
SPXOTSHWBDUUMT-UHFFFAOYSA-N 138-42-1 Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-N 0.000 description 1
OKRROXQXGNEUSS-UHFFFAOYSA-N 1h-imidazol-1-ium-1-carboxylate Chemical compound OC(=O)N1C=CN=C1 OKRROXQXGNEUSS-UHFFFAOYSA-N 0.000 description 1
LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
OTMCUVMOTJXGIY-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)ethyl 4-methylbenzenesulfonate Chemical compound N1=C(C)C=C(C)N1CCOS(=O)(=O)C1=CC=C(C)C=C1 OTMCUVMOTJXGIY-UHFFFAOYSA-N 0.000 description 1
IWZZXQSGHSQYBJ-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)ethyl imidazole-1-carboxylate Chemical compound C1CN(C(=O)C)CCN1CCOC(=O)N1C=NC=C1 IWZZXQSGHSQYBJ-UHFFFAOYSA-N 0.000 description 1
MHNWCBOXPOLLIB-UHFFFAOYSA-N 2-(bromomethyl)oxane Chemical compound BrCC1CCCCO1 MHNWCBOXPOLLIB-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
JVYROUWXXSWCMI-UHFFFAOYSA-N 2-bromo-1,1-difluoroethane Chemical compound FC(F)CBr JVYROUWXXSWCMI-UHFFFAOYSA-N 0.000 description 1
XQJAHBHCLXUGEP-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C=C1 XQJAHBHCLXUGEP-UHFFFAOYSA-N 0.000 description 1
KRVGXFREOJHJAX-UHFFFAOYSA-N 2-bromo-1-(4-methylphenyl)ethanone Chemical compound CC1=CC=C(C(=O)CBr)C=C1 KRVGXFREOJHJAX-UHFFFAOYSA-N 0.000 description 1
UJZWJOQRSMOFMA-UHFFFAOYSA-N 2-chloro-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C=C1 UJZWJOQRSMOFMA-UHFFFAOYSA-N 0.000 description 1
PPPIAEPDQPCIIM-UHFFFAOYSA-N 2-chloro-1-(4-hydroxyphenyl)ethanone Chemical compound OC1=CC=C(C(=O)CCl)C=C1 PPPIAEPDQPCIIM-UHFFFAOYSA-N 0.000 description 1
WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
JEQIUOSLBOSOPN-UHFFFAOYSA-N 3-ethylsulfonylpropan-1-ol Chemical compound CCS(=O)(=O)CCCO JEQIUOSLBOSOPN-UHFFFAOYSA-N 0.000 description 1
SJNFMGBQEOYAFH-UHFFFAOYSA-N 4-(1-hydroxybut-3-enyl)benzonitrile Chemical compound C=CCC(O)C1=CC=C(C#N)C=C1 SJNFMGBQEOYAFH-UHFFFAOYSA-N 0.000 description 1
RBSJBNYPTGMZIH-UHFFFAOYSA-N 4-(2-hydroxyethyl)benzonitrile Chemical compound OCCC1=CC=C(C#N)C=C1 RBSJBNYPTGMZIH-UHFFFAOYSA-N 0.000 description 1
ZIUYNDUOFPXUOD-UHFFFAOYSA-N 4-(3-bromopropoxy)benzonitrile Chemical compound BrCCCOC1=CC=C(C#N)C=C1 ZIUYNDUOFPXUOD-UHFFFAOYSA-N 0.000 description 1
WPOPTIIJKVHDCY-UHFFFAOYSA-N 4-(3-bromopropoxy)benzonitrile;1,3-dibromopropane Chemical compound BrCCCBr.BrCCCOC1=CC=C(C#N)C=C1 WPOPTIIJKVHDCY-UHFFFAOYSA-N 0.000 description 1
PLSFJPJQEAAVRM-UHFFFAOYSA-N 4-(4-hydroxybutyl)benzonitrile Chemical compound OCCCCC1=CC=C(C#N)C=C1 PLSFJPJQEAAVRM-UHFFFAOYSA-N 0.000 description 1
LAGMBWGVPMDMBP-UHFFFAOYSA-N 4-(benzenesulfonyl)-2,6-bis(iodomethyl)morpholine Chemical compound C1C(CI)OC(CI)CN1S(=O)(=O)C1=CC=CC=C1 LAGMBWGVPMDMBP-UHFFFAOYSA-N 0.000 description 1
UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
CIICLJLSRUHUBY-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]phenol Chemical compound CC(C)(C)OC1=CC=C(O)C=C1 CIICLJLSRUHUBY-UHFFFAOYSA-N 0.000 description 1
DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
WNIAOHACTUJSLN-UHFFFAOYSA-N 4-but-3-enylbenzonitrile Chemical compound C=CCCC1=CC=C(C#N)C=C1 WNIAOHACTUJSLN-UHFFFAOYSA-N 0.000 description 1
HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 1
MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
QESYLFCJDFCRIT-UHFFFAOYSA-N 4-hydroxybenzene-1,3-dicarbonitrile Chemical compound OC1=CC=C(C#N)C=C1C#N QESYLFCJDFCRIT-UHFFFAOYSA-N 0.000 description 1
ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
MVPUXVBBHWUOFS-UHFFFAOYSA-N 4-sulfanylbenzonitrile Chemical compound SC1=CC=C(C#N)C=C1 MVPUXVBBHWUOFS-UHFFFAOYSA-N 0.000 description 1
LJBSKUABXVDRGS-UHFFFAOYSA-N 5-(2-chloroethyl)-1h-imidazole Chemical compound ClCCC1=CN=CN1 LJBSKUABXVDRGS-UHFFFAOYSA-N 0.000 description 1
MIAHXWVABDHISZ-UHFFFAOYSA-N 6-(2-chloroacetyl)-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(C(=O)CCl)=CC=C21 MIAHXWVABDHISZ-UHFFFAOYSA-N 0.000 description 1
HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical compound OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
SWHOSKHDXHPCST-UHFFFAOYSA-N C(CC=C)C1=CC=C(C#N)C=C1.OCCCCC1=CC=C(C#N)C=C1 Chemical compound C(CC=C)C1=CC=C(C#N)C=C1.OCCCCC1=CC=C(C#N)C=C1 SWHOSKHDXHPCST-UHFFFAOYSA-N 0.000 description 1
LJHZUVQQMSZOOT-UHFFFAOYSA-N CC1=CC=NC=C1.ClCCCCC1=CC=NC=C1 Chemical compound CC1=CC=NC=C1.ClCCCCC1=CC=NC=C1 LJHZUVQQMSZOOT-UHFFFAOYSA-N 0.000 description 1
NRSKLCCINAQQQL-UHFFFAOYSA-N CCN(CC)S.F.F.F Chemical compound CCN(CC)S.F.F.F NRSKLCCINAQQQL-UHFFFAOYSA-N 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
DOJXGHGHTWFZHK-UHFFFAOYSA-N Hexachloroacetone Chemical compound ClC(Cl)(Cl)C(=O)C(Cl)(Cl)Cl DOJXGHGHTWFZHK-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
229910003298 Ni-Ni Inorganic materials 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000159610 Roya <green alga> Species 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
238000005644 Wolff-Kishner reduction reaction Methods 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
ZLQRCDUCUQIRPF-UHFFFAOYSA-N [4-(4-cyanophenyl)-4-(3,4-dimethoxyphenoxy)butyl] methanesulfonate Chemical compound C1=C(OC)C(OC)=CC=C1OC(CCCOS(C)(=O)=O)C1=CC=C(C#N)C=C1 ZLQRCDUCUQIRPF-UHFFFAOYSA-N 0.000 description 1
ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
WRYNUJYAXVDTCB-UHFFFAOYSA-M acetyloxymercury Chemical compound CC(=O)O[Hg] WRYNUJYAXVDTCB-UHFFFAOYSA-M 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
WEDIIKBPDQQQJU-UHFFFAOYSA-N butane-1-sulfonyl chloride Chemical compound CCCCS(Cl)(=O)=O WEDIIKBPDQQQJU-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000011128 cardiac conduction Effects 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
239000003245 coal Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000012351 deprotecting agent Substances 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
229960002994 dofetilide Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000013504 emergency use authorization Methods 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
230000020169 heat generation Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000016507 interphase Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
241000238565 lobster Species 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
ZUZLIXGTXQBUDC-UHFFFAOYSA-N methyltrioctylammonium Chemical compound CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC ZUZLIXGTXQBUDC-UHFFFAOYSA-N 0.000 description 1
XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
230000021962 pH elevation Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000019252 potassium sulphite Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
JTTWNTXHFYNETH-UHFFFAOYSA-N propyl 4-methylbenzenesulfonate Chemical compound CCCOS(=O)(=O)C1=CC=C(C)C=C1 JTTWNTXHFYNETH-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000012264 purified product Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000006462 rearrangement reaction Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000004467 single crystal X-ray diffraction Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
229960001922 sodium perborate Drugs 0.000 description 1
239000012418 sodium perborate tetrahydrate Substances 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
IBDSNZLUHYKHQP-UHFFFAOYSA-N sodium;3-oxidodioxaborirane;tetrahydrate Chemical compound O.O.O.O.[Na+].[O-]B1OO1 IBDSNZLUHYKHQP-UHFFFAOYSA-N 0.000 description 1
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
OSMADJAEHVCZKN-UHFFFAOYSA-N tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CBr OSMADJAEHVCZKN-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
150000004794 vinyl magnesium halides Chemical class 0.000 description 1
238000006886 vinylation reaction Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Heart & Thoracic Surgery (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

UA2002043168A 1999-10-18 2000-10-13 Oxabispidine compounds being useful in treatment of cardiac arrhythmias UA75052C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9903759A SE9903759D0 (sv)	1999-10-18	1999-10-18	Pharmaceutically active compounds
PCT/SE2000/001994 WO2001028992A2 (en)	1999-10-18	2000-10-13	New oxabispidine compounds useful in the treatment of cardiac arrhythmias

Publications (1)

Publication Number	Publication Date
UA75052C2 true UA75052C2 (en)	2006-03-15

Family

ID=20417401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002043168A UA75052C2 (en)	1999-10-18	2000-10-13	Oxabispidine compounds being useful in treatment of cardiac arrhythmias

Country Status (41)

Country	Link
US (6)	US6559143B1 (et)
EP (2)	EP1559717A3 (et)
JP (3)	JP3973906B2 (et)
KR (1)	KR100796142B1 (et)
CN (2)	CN101265262A (et)
AP (1)	AP1536A (et)
AR (2)	AR026064A1 (et)
AT (1)	ATE292134T1 (et)
AU (1)	AU769513B2 (et)
BG (1)	BG65785B1 (et)
BR (1)	BR0014804A (et)
CA (1)	CA2386910A1 (et)
CO (1)	CO5271655A1 (et)
CU (1)	CU23210A3 (et)
CZ (1)	CZ20021328A3 (et)
DE (1)	DE60019158T2 (et)
DK (1)	DK1235831T3 (et)
EA (1)	EA005319B1 (et)
EE (1)	EE04854B1 (et)
ES (1)	ES2239047T3 (et)
HK (1)	HK1049003B (et)
HR (1)	HRP20020336B1 (et)
HU (1)	HUP0204085A3 (et)
IL (5)	IL149108A0 (et)
IS (2)	IS2224B (et)
MX (1)	MXPA02003848A (et)
MY (1)	MY130661A (et)
NO (1)	NO327977B1 (et)
NZ (2)	NZ531260A (et)
OA (1)	OA12067A (et)
PL (1)	PL354970A1 (et)
PT (1)	PT1235831E (et)
RS (1)	RS50760B (et)
SE (1)	SE9903759D0 (et)
SI (1)	SI1235831T1 (et)
SK (1)	SK286723B6 (et)
TR (1)	TR200201059T2 (et)
TW (1)	TWI283680B (et)
UA (1)	UA75052C2 (et)
WO (1)	WO2001028992A2 (et)
ZA (1)	ZA200202575B (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9902270D0 (sv) *	1999-06-16	1999-06-16	Astra Ab	Pharmaceutically active compounds
SE9903759D0 (sv)	1999-10-18	1999-10-18	Astra Ab	Pharmaceutically active compounds
AR030756A1 (es) *	2000-10-02	2003-09-03	Astrazeneca Ab	Compuesto de oxabispidina util en el tratamiento de arritmias cardiacas
SE0101324D0 (sv) *	2001-04-12	2001-04-12	Astrazeneca Ab	New process
TWI259836B (en) *	2001-04-12	2006-08-11	Astrazeneca Ab	Modified release formulation suitable for antiarrhythmic compounds
SE0101329D0 (sv) *	2001-04-12	2001-04-12	Astrazeneca Ab	Pharmaceutical formulation
SE0101327D0 (sv) *	2001-04-12	2001-04-12	Astrazeneca Ab	New crystalline forms
SE0101323D0 (sv) *	2001-04-12	2001-04-12	Astrazeneca Ab	New process
EP1468001A1 (en) *	2001-11-22	2004-10-20	AstraZeneca AB	Process for the preparation of 2-or-9-oxa-3,7-diazabicyclo(3.3.1)nonanes from 2-aminomethyl-2,3-dihydrooxazines, intermediates therefore, and processes for preparing such intermediates
SE0201373D0 (sv) *	2002-05-06	2002-05-06	Astrazeneca Ab	Combination therapy
SE0201374D0 (sv) *	2002-05-06	2002-05-06	Astrazeneca Ab	Pharmaceutical combination
SE0201662D0 (sv) *	2002-05-31	2002-05-31	Astrazeneca Ab	Pharmaceutical combination
GB0223712D0 (en) *	2002-10-14	2002-11-20	Astrazeneca Ab	Chemical intermediate
SE0401539D0 (sv) *	2004-06-15	2004-06-15	Astrazeneca Ab	New compounds
SE0401540D0 (sv) *	2004-06-15	2004-06-15	Astrazeneca Ab	New compounds
CN101243093A (zh)	2005-06-13	2008-08-13	阿斯利康(瑞典)有限公司	用于治疗心律不齐的新型氧杂双哌啶化合物
WO2006137772A1 (en) *	2005-06-20	2006-12-28	Astrazeneca Ab	New physical form of n,n´- disubstituted oxabispidines
AR054391A1 (es) *	2005-06-20	2007-06-20	Astrazeneca Ab	Procedimiento para la preparacion de 3,7- dihidroxi-1,5-diazaciclooctanos
EP1915380A4 (en) *	2005-06-20	2010-03-17	Astrazeneca Ab	PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
AR054284A1 (es) *	2005-06-20	2007-06-13	Astrazeneca Ab	Procedimiento para la preparacion de sales de acido sulfonico de oxabispidinas
CN1330636C (zh) *	2005-09-26	2007-08-08	鲁南制药集团股份有限公司	盐酸替罗非班中间体的合成方法
TW200734342A (en) *	2005-12-15	2007-09-16	Astrazeneca Ab	New compounds for the treatment of cardiac arrhythmias
TW201004963A (en) *	2008-07-03	2010-02-01	Targacept Inc	Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands
GB2495308B (en) *	2011-10-05	2014-09-10	John Royce	Method and apparatus for cleaning a filter
CN105073728A (zh)	2013-03-15	2015-11-18	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
US10231970B2 (en)	2014-09-30	2019-03-19	NV Heterocycles	Methods of producing heteropolycycles via bis-epoxidation
JP2023101256A (ja) *	2022-01-07	2023-07-20	三菱ケミカル株式会社	エポキシ樹脂組成物及び硬化物
JP7800143B2 (ja) *	2022-01-07	2026-01-16	三菱ケミカル株式会社	エポキシ樹脂組成物及び硬化物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3196154A (en)	1962-05-17	1965-07-20	Sterling Drug Inc	3-substituted-9-methyl-3, 9-diazabicyclo [3.3.1] nonanes
US3503939A (en)	1967-03-29	1970-03-31	Du Pont	Polyamides from heterocyclic diamines
CH488048A (de)	1969-06-12	1970-03-31	Inventa Ag	Verfahren zur Herstellung von Polyesterfasern mit verbesserter Gummihaftung
JPS5772977A (en) *	1980-10-23	1982-05-07	Dainippon Ink & Chem Inc	Fluorine-containing diepoxy compound and its preparation
DE3112055A1 (de)	1981-03-27	1982-10-07	Basf Ag, 6700 Ludwigshafen	Bispidinderivate, ihre herstellung und diese enthaltende arzneimittel
US4533713A (en) *	1983-05-06	1985-08-06	Minnesota Mining And Manufacturing Company	Fluoroaliphaticsulfonamides containing oxirane groups and/or N-β-hydroxyalkylene groups
FI67320C (fi) *	1983-05-09	1985-03-11	Partek Ab	Foerfarande och glidgjutanordning foer gjutning av betongstycken
JPS6284071A (ja) *	1985-10-07	1987-04-17	Kanegafuchi Chem Ind Co Ltd	新規グリシジル化合物及びその製造方法
JPS6284070A (ja) *	1985-10-07	1987-04-17	Kanegafuchi Chem Ind Co Ltd	新規なグリシジル化合物及びその製造法
DE3732094A1 (de)	1987-09-24	1989-04-06	Basf Ag	Bispidinderivate als klasse iii-antiarrhythmika
US5140033A (en)	1989-04-03	1992-08-18	Bayer Aktiengesellschaft	Antibacterial 5-alkylquinolonecarboxylic acids
US5110933A (en)	1989-11-13	1992-05-05	Board Of Regents Of Oklahoma State University	Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
FR2664270B1 (fr) *	1990-07-09	1994-04-08	Norsolor Sa	Nouveaux composes (meth)acryliques porteurs de fonction thiocyanate, leur procede de preparation et leur application a l'obtention de nouveaux polymeres.
JP2602745B2 (ja) *	1991-06-26	1997-04-23	花王株式会社	フレキシブルディスク用センターハブのピッキング装置
US5468858A (en) *	1993-10-28	1995-11-21	The Board Of Regents Of Oklahoma State University Physical Sciences	N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
US5831099A (en)	1995-03-10	1998-11-03	The United States Of America As Represented By The Secretary Of The Army	Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
SE9704709D0 (sv) *	1997-12-17	1997-12-17	Astra Ab	Pharmaceutically active compounds
SE9803517D0 (sv) *	1998-10-15	1998-10-15	Astra Ab	Pharmaceutical preparation
CN1147483C (zh)	1999-04-09	2004-04-28	阿斯特拉曾尼卡有限公司	金刚烷衍生物
SE9902270D0 (sv) *	1999-06-16	1999-06-16	Astra Ab	Pharmaceutically active compounds
SE9903759D0 (sv) *	1999-10-18	1999-10-18	Astra Ab	Pharmaceutically active compounds
SE9904765D0 (sv) *	1999-12-23	1999-12-23	Astra Ab	Pharmaceutically-useful compounds
AR030756A1 (es) *	2000-10-02	2003-09-03	Astrazeneca Ab	Compuesto de oxabispidina util en el tratamiento de arritmias cardiacas

1999
- 1999-10-18 SE SE9903759A patent/SE9903759D0/xx unknown
2000
- 2000-10-06 TW TW089120910A patent/TWI283680B/zh not_active IP Right Cessation
- 2000-10-13 HU HU0204085A patent/HUP0204085A3/hu unknown
- 2000-10-13 SI SI200030681T patent/SI1235831T1/xx unknown
- 2000-10-13 CA CA002386910A patent/CA2386910A1/en not_active Abandoned
- 2000-10-13 DK DK00971960T patent/DK1235831T3/da active
- 2000-10-13 BR BR0014804-0A patent/BR0014804A/pt not_active IP Right Cessation
- 2000-10-13 DE DE60019158T patent/DE60019158T2/de not_active Expired - Lifetime
- 2000-10-13 CN CNA2008100058488A patent/CN101265262A/zh active Pending
- 2000-10-13 EE EEP200200203A patent/EE04854B1/et not_active IP Right Cessation
- 2000-10-13 UA UA2002043168A patent/UA75052C2/uk unknown
- 2000-10-13 IL IL14910800A patent/IL149108A0/xx unknown
- 2000-10-13 PT PT00971960T patent/PT1235831E/pt unknown
- 2000-10-13 WO PCT/SE2000/001994 patent/WO2001028992A2/en not_active Ceased
- 2000-10-13 KR KR1020027004902A patent/KR100796142B1/ko not_active Expired - Fee Related
- 2000-10-13 HR HR20020336A patent/HRP20020336B1/xx not_active IP Right Cessation
- 2000-10-13 ES ES00971960T patent/ES2239047T3/es not_active Expired - Lifetime
- 2000-10-13 NZ NZ531260A patent/NZ531260A/en unknown
- 2000-10-13 EA EA200200390A patent/EA005319B1/ru not_active IP Right Cessation
- 2000-10-13 AU AU10691/01A patent/AU769513B2/en not_active Ceased
- 2000-10-13 CZ CZ20021328A patent/CZ20021328A3/cs unknown
- 2000-10-13 EP EP05006781A patent/EP1559717A3/en not_active Withdrawn
- 2000-10-13 PL PL00354970A patent/PL354970A1/xx not_active Application Discontinuation
- 2000-10-13 EP EP00971960A patent/EP1235831B1/en not_active Expired - Lifetime
- 2000-10-13 OA OA1200200113A patent/OA12067A/en unknown
- 2000-10-13 NZ NZ518156A patent/NZ518156A/en unknown
- 2000-10-13 RS YUP-294/02A patent/RS50760B/sr unknown
- 2000-10-13 TR TR2002/01059T patent/TR200201059T2/xx unknown
- 2000-10-13 JP JP2001531792A patent/JP3973906B2/ja not_active Expired - Fee Related
- 2000-10-13 AP APAP/P/2002/002471A patent/AP1536A/en active
- 2000-10-13 CN CNB00816231XA patent/CN100379743C/zh not_active Expired - Fee Related
- 2000-10-13 HK HK03101241.2A patent/HK1049003B/en not_active IP Right Cessation
- 2000-10-13 MX MXPA02003848A patent/MXPA02003848A/es active IP Right Grant
- 2000-10-13 AT AT00971960T patent/ATE292134T1/de not_active IP Right Cessation
- 2000-10-13 SK SK506-2002A patent/SK286723B6/sk not_active IP Right Cessation
- 2000-10-16 US US09/688,251 patent/US6559143B1/en not_active Expired - Fee Related
- 2000-10-16 MY MYPI20004850A patent/MY130661A/en unknown
- 2000-10-17 CO CO00078740A patent/CO5271655A1/es not_active Application Discontinuation
- 2000-10-17 AR ARP000105452A patent/AR026064A1/es active IP Right Grant
2002
- 2002-04-02 ZA ZA200202575A patent/ZA200202575B/en unknown
- 2002-04-05 BG BG106588A patent/BG65785B1/bg unknown
- 2002-04-11 IL IL183854A patent/IL183854A0/en unknown
- 2002-04-11 IL IL149108A patent/IL149108A/en not_active IP Right Cessation
- 2002-04-16 CU CU20020079A patent/CU23210A3/es not_active IP Right Cessation
- 2002-04-17 NO NO20021811A patent/NO327977B1/no not_active IP Right Cessation
- 2002-04-17 IS IS6346A patent/IS2224B/is unknown
- 2002-12-12 US US10/317,195 patent/US7164017B2/en not_active Expired - Fee Related
2003
- 2003-04-02 AR ARP030101150A patent/AR039226A2/es unknown
2006
- 2006-03-22 US US11/385,861 patent/US20060166980A1/en not_active Abandoned
- 2006-03-22 US US11/385,833 patent/US7772229B2/en not_active Expired - Fee Related
- 2006-08-23 JP JP2006226089A patent/JP2006342182A/ja active Pending
- 2006-12-18 US US11/640,417 patent/US7351821B2/en not_active Expired - Fee Related
- 2006-12-27 IS IS8586A patent/IS8586A/is unknown
2007
- 2007-03-28 JP JP2007083302A patent/JP2007204486A/ja active Pending
- 2007-06-11 IL IL183853A patent/IL183853A0/en unknown
- 2007-06-11 IL IL183852A patent/IL183852A0/en unknown
2009
- 2009-09-01 US US12/585,029 patent/US20090326221A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030153564A1 (en)	2003-08-14
HK1049003A1 (en)	2003-04-25
NO20021811L (no)	2002-06-06
SE9903759D0 (sv)	1999-10-18
HUP0204085A3 (en)	2006-01-30
KR100796142B1 (ko)	2008-01-21
HRP20020336B1 (en)	2006-02-28
PT1235831E (pt)	2005-06-30
SI1235831T1 (et)	2005-08-31
EE04854B1 (et)	2007-06-15
CN100379743C (zh)	2008-04-09
EP1559717A3 (en)	2009-04-29
ZA200202575B (en)	2003-09-23
MY130661A (en)	2007-07-31
EP1235831A2 (en)	2002-09-04
RS50760B (sr)	2010-08-31
US20090326221A1 (en)	2009-12-31
EE200200203A (et)	2003-06-16
HRP20020336A2 (en)	2004-02-29
CN1399639A (zh)	2003-02-26
JP2003512352A (ja)	2003-04-02
JP2007204486A (ja)	2007-08-16
SK5062002A3 (en)	2002-11-06
MXPA02003848A (es)	2002-10-23
NZ518156A (en)	2004-05-28
EA005319B1 (ru)	2005-02-24
IL149108A (en)	2009-12-24
EP1559717A2 (en)	2005-08-03
US6559143B1 (en)	2003-05-06
IL183852A0 (en)	2009-02-11
JP3973906B2 (ja)	2007-09-12
IS6346A (is)	2002-04-17
EP1235831B1 (en)	2005-03-30
PL354970A1 (en)	2004-03-22
AU769513B2 (en)	2004-01-29
US7164017B2 (en)	2007-01-16
IL183854A0 (en)	2009-02-11
ATE292134T1 (de)	2005-04-15
TR200201059T2 (tr)	2002-09-23
IS8586A (is)	2006-12-27
NZ531260A (en)	2005-08-26
WO2001028992A3 (en)	2001-09-13
SK286723B6 (sk)	2009-04-06
IS2224B (is)	2007-04-15
DE60019158D1 (de)	2005-05-04
BR0014804A (pt)	2002-06-11
EA200200390A1 (ru)	2002-10-31
AU1069101A (en)	2001-04-30
TWI283680B (en)	2007-07-11
OA12067A (en)	2006-05-04
DE60019158T2 (de)	2006-02-02
AR026064A1 (es)	2002-12-26
NO327977B1 (no)	2009-11-02
US20060166979A1 (en)	2006-07-27
BG106588A (en)	2003-01-31
US20070117799A1 (en)	2007-05-24
CA2386910A1 (en)	2001-04-26
IL149108A0 (en)	2002-11-10
IL183853A0 (en)	2009-02-11
WO2001028992A2 (en)	2001-04-26
CN101265262A (zh)	2008-09-17
HUP0204085A2 (hu)	2003-04-28
US7772229B2 (en)	2010-08-10
ES2239047T3 (es)	2005-09-16
US7351821B2 (en)	2008-04-01
BG65785B1 (bg)	2009-11-30
AP1536A (en)	2006-01-09
CZ20021328A3 (cs)	2002-09-11
KR20020038956A (ko)	2002-05-24
DK1235831T3 (da)	2005-06-27
HK1049003B (en)	2005-09-09
AP2002002471A0 (en)	2002-06-30
NO20021811D0 (no)	2002-04-17
YU29402A (sh)	2004-12-31
CU23210A3 (es)	2007-06-20
US20060166980A1 (en)	2006-07-27
AR039226A2 (es)	2005-02-09
JP2006342182A (ja)	2006-12-21
CO5271655A1 (es)	2003-04-30

Publication	Publication Date	Title
UA75052C2 (en)	2006-03-15	Oxabispidine compounds being useful in treatment of cardiac arrhythmias
AU2020323429B2 (en)	2025-06-26	Urea compound for antagonizing LPA1 receptor
CA2003422C (en)	1999-12-21	Quinuclidines, their use as medicaments and processes for their preparation
EP3040331B1 (en)	2018-11-14	Tetrahydrocyclopentapyrrole derivative and preparation method therefor
WO2023154913A1 (en)	2023-08-17	Inhibitors of parg
CN110627812B (zh)	2022-10-11	作为trk抑制剂的杂环化合物
CN106573001A (zh)	2017-04-19	作为蛋白激酶抑制剂的氨基哒嗪酮化合物
TW201016708A (en)	2010-05-01	Novel fused aminodihydrothiazine derivative
TW200936577A (en)	2009-09-01	Phthalazinone derivatives
UA125120C2 (uk)	2022-01-12	Модулятори бeta-3 адренергічного рецептора, корисного при лікуванні та профілактиці опосередкованих ним розладів
TW200531972A (en)	2005-10-01	Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
TW201702226A (zh)	2017-01-16	尿素衍生物或其醫藥上可接受鹽
EP3625234B1 (en)	2023-09-20	Hexahydropyrazolo [1,2-a] diazepinones and related heterocycles as inhibitors of rip-1 kinase
UA123789C2 (uk)	2021-06-02	Тетрагідропіримідодіазепін і тетрагідропіридодіазепін сполуки для лікування болю та станів, пов'язаних з болем
AU2023218939A1 (en)	2024-08-22	4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
UA75057C2 (en)	2006-03-15	Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias, a method for obtaining thereof (variants), pharmaceutical composition based thereon and intermediary compound
SK9702003A3 (en)	2004-01-08	3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
WO2024173234A1 (en)	2024-08-22	Inhibitors of parg
WO2020135454A1 (zh)	2020-07-02	一类类固醇化合物及其用途
CN108341816A (zh)	2018-07-31	一种选择性抑制激酶化合物
CZ20014495A3 (cs)	2002-05-15	Nové bispidinové sloučeniny, vhodné k léčení srdeční arytmie
JP7843780B2 (ja)	2026-04-10	癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体
JP2022506378A (ja)	2022-01-17	疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物
EP3658546B1 (en)	2022-10-26	Indole derivatives and uses thereof
CZ20014493A3 (cs)	2002-05-15	Nové bispidinové sloučeniny vhodné k léčení srdeční arytmie